Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia
Liposomal daunorubicin and cytarabine are effective as reinduction chemotherapy
October 25th, 2006
Liposomal daunorubicin (DNX) and cytarabine are effective as reinduction chemotherapy for relapsed acute lymphoblastic leukaemia (ALL) despite expression of multidrug resistance (MDR)-related proteins. According to recent research published in the European Journal of Haematology, "The treatment of relapsed adult ALL is frequently unsuccessful with current chemotherapy regimens, and often there is an overexpression of MDR-related proteins. Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that DNX (Daunoxome) is more toxic than DNR against ALL cell lines." A....
Source: Biotech Week (2006-10-25)
|
